Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

s and increasing their risk of developing treatment-related acute myeloid leukemia.

To understand if ibrutinib may be effective for elderly CLL patients and to identify which patients might benefit most from the drug, researchers enrolled 116 CLL patient participants in several treatment cohorts: patients who were never treated (the treatment-nave group), those who had received two or more prior therapies (the relapsed/refractory group), those who had relapsed within two years of treatment (the high-risk group), and those over age 65. Two oral dosing regimens (420 mg or 840 mg daily) of ibrutinib were used. The primary goal of the study was to determine the safety of the low and high doses; secondary objectives included efficacy, measures of the intensity of the drug's effect in the body, and the long-term safety of administering this therapy continuously until relapse.

The study found that response to therapy was high across the cohorts, with largely manageable toxicities. Previously untreated elderly patients responded best to the agent, with 71 percent experiencing a complete or partial response at either treatment dose. The same response was observed in 67 percent of the relapsed patients and 50 percent of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

The treatment regimen was generally well-tolerated, as only non-severe side effects were observed, including diarrhea, fatigue, chest infection, rash, nausea, joint pain, and infrequent and transient low blood counts. Investigators found no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients. These results demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL.

"As we learn more about how to target specific essential survival signa
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... 23, 2014 "I have heard female ... a urine sample," said an inventor from Lake Stevens, ... and mess-free, I came up with this urine-collection aid." ... samples to be collected from women more easily. The ... to patients and staff. The invention improves sanitation and ...
(Date:8/23/2014)... Peripheral intervention surgeries are part of ... thereby addressing the root cause of peripheral artery disease. ... the other part of the arteries where the blood ... require the use of a catheter, (which is a ... catheters are inserted through a thin cut in an ...
(Date:8/23/2014)... A team of New York researchers say ... preceded by surgery and delivered by an experienced team. Surviving ... Click here to read it now . , ... of mesothelioma patients who underwent hemithoracic (one side of ... the shape of a tumor. Patients who had surgery ...
(Date:8/23/2014)... GBI Research, the leading business intelligence provider, has ... Developed Markets to 2020 - New and Late-Stage Four-Factor ... in-depth analysis of the critical care market in the ... The report provides an estimation of market size for ... critical care indications that are being treated using the ...
(Date:8/23/2014)... Young adults in Athens, GA who find that they have a ... and call the new helpline which can offer support and guidance ... Teen Athens is a wonderful resource for an adolescent drug or ... to end substance abuse once and for all. When a young ... peers when really they should put their faith in a youth ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2
... own bone marrow stem cells after a heart attack ... Emory University School of Medicine physicians has found. , ... Emory University School of Medicine, presents the results Monday ... , "These results show that treatment with a patient,s ...
... highest channel-count 12-bit ADC reduces I/O pin ... SANTA CLARA, Calif., March 30 /PRNewswire/ ... mixed-signal compression solutions for intelligent data conversion, ... of analog-to-digital converters (ADCs) integrated with the ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... cash resources in order to maintain the ability to ... highly selective inhibitor of PTP1B and Genaera,s lead drug ... obesity, and explore strategic alternatives. The Company will ...
... 21 is pleased to announce that Michael A. ... elected to the board of directors of the ... a 128-year old trade association representing manufacturers and ... Members were elected at the association,s March ...
... Billion Each Year According to the Better Sleep CouncilDALLAS, March ... Unfortunately, sleep is usually one of the first things people ... In a turbulent economy, nearly 30 percent of Americans ... according to a 2009 Sleep in America poll by the ...
... A health insurance protocol intended to ... barriers that lead people to receive less of needed ... result, patients ultimately require more -- and more costly ... plan members to try a first-line medication before they ...
Cached Medicine News:Health News:After heart attack, bone marrow stem cells increase blood flow within heart 2Health News:Samplify Rolls Production Quantities of Its SAM1600 Analog/Digital Converters with Real-Time Data Compression 2Health News:Samplify Rolls Production Quantities of Its SAM1600 Analog/Digital Converters with Real-Time Data Compression 3Health News:Genaera Corporation Implements Cash Conservation Plan 2Health News:Nutrition 21's President and CEO, Elected to the Consumer Healthcare Products Association Board 2Health News:Nutrition 21's President and CEO, Elected to the Consumer Healthcare Products Association Board 3Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 2Health News:Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers 3
(Date:8/22/2014)... 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... and Panera (Nasdaq: PNRA - Free Report ) as the ... on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi ... SHPG - Free Report ). Here is a synopsis ... Day : The biotech bull market is far ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/21/2014)... Memorial Hermann Health System and The University of ... partnership to provide a new level of specialized breast screening ... greater Houston area. Starting ... of professional breast radiology services for five of Memorial Hermann,s ... The Woodlands , Northeast, Southwest and Sugar ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4
... NEW YORK, Dec. 14, 2010 Reportlinker.com ... is available in its catalogue: ... Electrophysiology & Ablation Devices 2011 ... In 2010, the Asia Pacific markets for ...
... YORK, Dec. 14, 2010 Reportlinker.com announces that a ... The Clinical Trials Business ... and the outsourcing of clinical trials to lower-cost countries ... the U.S. to a 3.3% compound annual growth rate ...
Cached Medicine Technology:Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds The Clinical Trials Business 2Reportlinker Adds The Clinical Trials Business 3Reportlinker Adds The Clinical Trials Business 4Reportlinker Adds The Clinical Trials Business 5Reportlinker Adds The Clinical Trials Business 6Reportlinker Adds The Clinical Trials Business 7Reportlinker Adds The Clinical Trials Business 8Reportlinker Adds The Clinical Trials Business 9Reportlinker Adds The Clinical Trials Business 10Reportlinker Adds The Clinical Trials Business 11Reportlinker Adds The Clinical Trials Business 12Reportlinker Adds The Clinical Trials Business 13
... from end, Cannula comes with 20cm (8 in) ... Capable of withstanding injections of viscoelastic fluids. ID-0.50mm ... lock, high pressure extension tubing set., 20cm (8 ... (Cannulas come with 20cm luer lock, high ...
Multi-sided, Sharp all around...
2.5mm...
...
Medicine Products: